Overview

The Effects of Insulin Detemir and Gliclazide-MR Treatments on Endothelial Functions in Patients With Type 2 Diabetes

Status:
Completed

Trial end date:
2012-06-01

Target enrollment:
0

Participant gender:
All

Summary

The main purpose of this study is to analyze the effects of the addition of sulfonylurea (gliclazide MR) or ,alternatively, basal insulin (insulin detemir) to life-style modification and metformin treatment as a second step treatment in type 2 diabetes mellitus on endothelial cell functions. The second goal is to identify the effects of these treatment alternatives on body-mass index, the changes in body fat mass, insulin resistance and on the insulin secretion capacity of beta cells. The third aim of this study is to determine the success rates of these treatment alternatives on glycemic control at 6 months follow-up.

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Ankara University

Collaborators:

Hacettepe University
The Scientific and Technological Research Council of Turkey
Tubitak

Treatments:

Gliclazide
Insulin
Insulin Detemir
Insulin, Globin Zinc

Criteria

Inclusion Criteria:

1. Type 2 diabetic patients using at least 1000 mg/day metformin at least for 3 months

2. 7
3. Patients without any previous use of oral antidiabetics other than metformin or
insulin

4. Between 20 to 65 years old male or female patients

Exclusion Criteria:

1. Active hepatic disease

2. Serum creatinin 1,5 mg/dl or more for males, 1,4 or more for females

3. Proliferative Diabetic Retinopathy

4. Coronary Artery Disease

5. Patients with any kind of diagnosed malignancy

6. Pregnancy and Lactation

7. Fasting C-peptide levels lower than 2.0 ng/ml

8. Smoking or drug abuse